News

The companies will work together in developing and commercializing novel therapeutics in the fields of cancer immunotherapy and inflammation. Amgen agreed to pay $45m upfront to license Xencor’s

The company carried out the trial at 12 sites in the US with 450 patients randomized to receive either ITI-007 60 mg or 40 mg or placebo once

GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s BEAT platform. The drug candidate has the potential to be used in the treatment of an array of

The company carried out the randomized, double-blind, placebo-controlled trial of XP23829 in 33 sites in the US in 200 subjects with moderate-to-severe chronic plaque-type psoriasis. They were randomized

Last month, InSite Vision signed a definite agreement with Canadian drug maker QLT for $0.25 and 0.30 per share. The deal however included a built in clause that

Alector has built a broad platform of new-generation therapeutics, which mobilize the immune system to eliminate multiple disease-causing pathologies. Alector co-founder Asa Abeliovich said: "We have developed a

The Phase 1 study is being performed in asymptomatic "high excreter" (ASHE) patients, who carry the genetic mutation of acute intermittent porphyria (AIP) and have elevated levels of

The product line provides a full assortment of hospital-quality products for consumers categorized as Advanced Wound Care, First Aid, Personal Care, and Home Healthcare which help provide comfort

Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of Factor Xa inhibitors. Portola is